Evaluation of Pharmaceutical Care in Depressed Outpatients
Not Applicable
- Conditions
- Depression
- Interventions
- Procedure: pharmacotherapeutic follow-up
- Registration Number
- NCT01571973
- Lead Sponsor
- Federal University of São Paulo
- Brief Summary
The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
- women between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)
Exclusion Criteria
- record of dependence on psychoactive substances, diagnosed schizophrenia,
- low education (illiterate) or cognitive impairment evident that compromise the completion of research instruments
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intervention group pharmacotherapeutic follow-up outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
- Primary Outcome Measures
Name Time Method depression level six months evaluation depression level by Beck scale
- Secondary Outcome Measures
Name Time Method anxiety level 6 months evaluation anxiety level by Beck scale.
compliance 6 months evaluation antidepressive treatment compliance by Morisky scale
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the effectiveness of pharmacotherapeutic follow-up in depression management?
How does the Dáder program compare to standard-of-care in treating major depressive disorder outpatient populations?
Are there specific biomarkers associated with improved outcomes in depression patients receiving pharmaceutical care?
What adverse events are commonly reported in depression trials involving psychotropic medication monitoring?
What combination therapies or alternative drug classes show promise alongside pharmaceutical follow-up for depression?